China Securities News (Reporter Deng Zhen) On November 28th, the Shanghai Securities News learned from Wanbangde that the company has been deeply engaged in the research and development of new drugs for Alzheimer's disease (AD) for many years, always committed to developing new therapeutic drugs for global AD patients. Currently, the II/III phase key registration clinical trial of the company's Selonyma Hydrochloride Controlled-release Tablets (FN12) is progressing smoothly. This clinical study is the largest Alzheimer's disease registration study known in China. The company actively collaborates closely with CRO companies (contract research organizations for pharmaceutical development) to strive to obtain more effective data as soon as possible to verify the efficacy and safety of the drug.

Existing data shows that Selonyma Hydrochloride Controlled-release Tablets have good safety. Selonyma, at an appropriate dose, can significantly improve the cognitive function of patients. At the same time, preclinical research shows that Selonyma not only can increase the level of choline in the brain, but also has anti-inflammatory, antioxidant, reducing the level of β-amyloid protein, mitochondrial protection, and neuroprotective effects. Therefore, the company believes that Selonyma Controlled-release Tablets are expected to bring differentiated and comprehensive benefits to global AD patients.

It is introduced that Wanbangde's new peptide drugs are completely new compound Class 1 drugs, which work by acting on different targets (such as melanocortin receptors). In preclinical animal experimental studies, this new peptide drug shows excellent weight loss effects, while also reducing blood sugar, glycosylated hemoglobin, diabetes kidney disease indicators, and diabetes retinopathy indicators. In addition, in the pemphigus model, this new peptide drug shows significantly better effects than glucocorticoids and has received orphan drug recognition from the US FDA.

The company has also conducted preclinical research on Alzheimer's disease. The results show that the cyclic peptide drug can significantly improve the paralysis level of the model with excessive β-amyloid protein expression and can extend life. The progress of the company's project on the peptide drug for AD is positive, demonstrating its strategic layout in the Alzheimer's disease field, based on the existing Selonyma Controlled-release Tablets, to further study new targets, new compounds, and new action mechanisms of drugs. It hopes to reach a new height in the global Alzheimer's disease drug research and development.
https://finance.eastmoney.com/a/202511283577693994.html